# Alphyn Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alphyn-biologics

- Industry: Biotechnology
- Headquarters: Annapolis, US
- Website: www.alphynbiologics.com/
- Total disclosed funding: $28M
- Latest round: Series B (Dec 12, 2025)
- Investors on record: 3

## About

Based in Maryland, US, and founded in 2019 by Neal Koller (CEO), Alphyn Biologics, Inc. Fka Alphyn Biologics, LLC, operates as a dermatology company that improves people's lives by curing the most difficult, severe skin diseases. In December 2025, Alphyn Biologics raised 25 million in series B funding led by Queen City Angels, with participation from Angel Physicians Fund and Serial Stage Venture Partners. Alphyn Biologics created a product called AB-101's that offers numerous benefits such as pre-clinical testing requirements, animal testing requirements, moving directly to Phase 2 human clinical trials, and so on. The AB-101 platform biomaterial will be used to target the most difficult, severe, and prevalent skin diseases confronting humanity. Furthermore, atopic dermatitis is AB-101's first target disease (or AD, also known as Eczema). The company generates revenue through licensing, partnerships, and milestone payments for dermatology therapeutics. The company plans to use the December 2025 funding to support its global Phase 2b trial for atopic dermatitis, start a Phase 2 programme for molluscum contagiosum, and expand raw material supply.

## Funding rounds

- Series B, Dec 12, 2025, $25M — Queen City Angels, Angel Physicians Fund
- Series A, Sep 15, 2022, $3.3M — Queen City Angels, Stage Venture Partners, Angel Physicians Fund

## Investors

- Queen City Angels (https://capitalatlas.ai/funds/queen-city-angels) — Series A, Series B
- Stage Venture Partners (https://capitalatlas.ai/funds/stage-venture-partners) — Series A
- Angel Physicians Fund (https://capitalatlas.ai/funds/angel-physicians-fund) — Series A, Series B